Volume 5, Issue 10: CFTR-Modifying Therapies PODCAST
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 10)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Explain the relevance of specific mutations in people with CF to new therapies currently available or likely to be approved in the near future.
- Identify which patients are suitable for disease modifying therapies based on mutation class.
- Evaluate the clinical trial data on the use of combination disease modifying therapy in patients with CF and who are homozygous for the F508del mutation.
Dr. Stuart Elborn has disclosed that he has served as a consultant for Vertex. He has received research support from Vertex, Gilead, and Novartis. In addition, his institution has a consortium with Boehringer.
Dr. Stuart Elborn has disclosed that he will discuss off label or unapproved uses of lumcaftor, ivacaftor, and ataluren.
- 0.50 ANCC
- 0.50 Attendance